Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label, Randomized, Two-Sequence, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adult Participants

NCT07510529 is registered in ClinicalTrials.gov with Simcere Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07510529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07510529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label, Randomized, Two-Sequence, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adult Participants
Lead sponsor
Simcere Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 20, 2026
Completion date
June 30, 2026
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants